<DOC>
	<DOCNO>NCT00585650</DOCNO>
	<brief_summary>The purpose research study see well ( compare placebo ) Enbrel® ( etanercept ) 50 mg twice week affect plaque psoriasis hand and/or foot ( Palmoplantar Psoriasis )</brief_summary>
	<brief_title>Study Tumor Necrosis Factor Receptor Fusion Protein Etanercept ( Enbrel ) Psoriasis Hands and/or Feet</brief_title>
	<detailed_description>This 24-week multicenter study consist two phase . The first phase 12 week , double-blind , randomize trial etanercept , 50 mg twice weekly versus placebo subject PPP . Subjects meet eligibility criterion randomize either 50 mg etanercept twice weekly placebo . Subcutaneous injection occur twice weekly approximately time day first 12-week treatment period . The primary efficacy endpoint assess 12 week treatment . At end first 12 week , patient ( treatment placebo arm ) treat etanercept 50 mg twice week ( BIW ) additional 12 week .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Moderate severe palmar plantar psoriasis base physician 's global assessment ( PGA ) . Between 18 70 year age Negative urine pregnancy test screen baseline Sexually active men woman childbearing potential must agree use medically accept form contraception ( birth control ) exclusionary medicine washout period throughout study . Ability self inject study drug designee Capable understanding give write voluntary inform consent Previous treatment Enbrel® ( etanercept ) similar drug Receipt investigational drug `` biologics '' within 4 week screen visit . Evidence skin condition ( e.g . eczema ) psoriasis would interfere evaluation study medication . Receipt biologic medication within previous 6 month result decreased white blood cell count ( cell help fight infection ) Ultraviolet light treatment ( e.g . UVB , PUVA ) within one month prior study drug initiation . Receipt immunesuppressing drug Rheumatrex® ( methotrexate ) Soriatane® ( acetretin ) within 4 week prior first dose study drug . Medications would allow take study include example , Cytoxan® ( cyclosporine ) , Imuran® ( azathioprine ) , Sulfazine® ( sulfasalazine ) . If remain Rheumatrex® ( methotrexate ) ( ≤25 mg/week ) Soriatane® ( acitretin ) ( ≤50 mg/day ) , must consider inadequate disease control opinion investigator base physician 's global assessment . You must stable dose systemic treatment least 1 month prior start study medication . You require maintain stable dose systemic treatment throughout study . Use topical steroid past 14 day unless use longer 14 day severity disease allow entry study . Systemic steroid use ( prednisone , etc ) . Prior concurrent use Cytoxan® ( cyclophosphamide ) . Elevated liver test ; red blood cell count less normal ; decrease platelet count ( cell help blood clot ) ; decrease white blood cell count ( cell fight infection ) ; kidney insufficiency Any severe adverse event , infection abnormal laboratory value time screen visit would preclude participation study Presence severe infection , less 30 day prior screen visit screen visit first dose study drug Pregnant breastfeeding female . Significant concurrent medical disease include : Uncompensated congestive heart failure ( heart unable pump normal ) : Myocardial infarction ( heart attack ) within 12 month screening period ; Unstable stable angina pectoris ( chest pain related heart ) ; Uncontrolled high blood pressure Severe lung disease require medical oxygen therapy History cancer ( surgically remove skin cancer situ cervical cancer ) within 5 year screen visit History tuberculosis Known HIV positive Rheumatoid arthritis Any neurologic demyelinating disease ( multiple sclerosis neurologic disease cause loss sensation loss normal movement ) seizure disorder Current history psychiatric disease would interfere ability comply study protocol give informed consent . History alcohol drug abuse . Not uptodate immunization agreement current immunization guideline Significant exposure varicella virus ( chicken pox ) Guttate generalize pustular psoriasis Surgery trauma within month baseline consider investigator represent significant risk interfere patient evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>palmoplantar psoriasis</keyword>
	<keyword>etanercept</keyword>
	<keyword>Enbrel</keyword>
</DOC>